Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence

Clinical Pharmacology and Therapeutics

Volumn 77, Issue 3, 2005, Pages 145-158

  Malaiyandi, Viba ^a   Sellers, Edward M ^a   Tyndale, Rachel F ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2A6; NICOTINE;

CANCER RISK; GENE FREQUENCY; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; REVIEW; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CANADA; HEALTH BEHAVIOR; HUMANS; MIXED FUNCTION OXYGENASES; NICOTINE; POLYMORPHISM, GENETIC; SMOKING; TOBACCO USE DISORDER;

EID: 13944284575     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.10.011     Document Type: Review

References (139)

1. J.E. Henningfield, K. Miyasato, D.R. Jasinski Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine J Pharmacol Exp Ther 234 1985 1 12
2. I.P. Stolerman, M.J. Jarvis The scientific case that nicotine is addictive Psychopharmacology (Berl) 117 1995 2 10, discussion 14-20
3. V.I. Pidoplichko, M. DeBiasi, J.T. Williams, J.A. Dani Nicotine activates and desensitizes midbrain dopamine neurons Nature 390 1997 401 404
4. F.E. Pontieri, G. Tanda, F. Orzi, G. Di Chiara Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs Nature 382 1996 255 257
5. R.K. Salokangas, H. Vilkman, T. Ilonen, T. Taiminen, J. Bergman, M. Haaparanta High levels of dopamine activity in the basal ganglia of cigarette smokers Am J Psychiatry 157 2000 632 634
6. S.R. Laviolette, D. van der Kooy Blockade of mesolimbic dopamine transmission dramatically increases sensitivity to the rewarding effects of nicotine in the ventral tegmental area Mol Psychiatry 8 2003 50 59
7. E.A. Stein, J. Pankiewicz, H.H. Harsch, J.K. Cho, S.A. Fuller, R.G. Hoffmann Nicotine-induced limbic cortical activation in the human brain: a functional MRI study Am J Psychiatry 155 1998 1009 1015
8. G.F. Koob Neurobiology of addiction Toward the development of new therapies Ann N Y Acad Sci 909 2000 170 185
9. T.B. Baker, T.H. Brandon, L. Chassin Motivational influences on cigarette smoking Annu Rev Psychol 55 2004 463 491
10. B. Buisson, D. Bertrand Nicotine addiction: the possible role of functional upregulation Trends Pharmacol Sci 23 2002 130 136
11. C.M. Flores, M.I. Davila-Garcia, Y.M. Ulrich, K.J. Kellar Differential regulation of neuronal nicotinic receptor binding sites following chronic nicotine administration J Neurochem 69 1997 2216 2219
12. D.C. Perry, M.I. Davila-Garcia, C.A. Stockmeier, K.J. Kellar Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies J Pharmacol Exp Ther 289 1999 1545 1552
13. M.P. Epping-Jordan, S.S. Watkins, G.F. Koob, A. Markou Dramatic decreases in brain reward function during nicotine withdrawal Nature 393 1998 76 79
14. V. Teneggi, S.T. Tiffany, L. Squassante, S. Milleri, L. Ziviani, A. Bye Smokers deprived of cigarettes for 72 h: effect of nicotine patches on craving and withdrawal Psychopharmacology (Berl) 164 2002 177 187
15. N.L. Benowitz Pharmacology of nicotine: addiction and therapeutics Annu Rev Pharmacol Toxicol 36 1996 597 613
16. M.J. Jarvis Why people smoke BMJ 328 2004 277 279
17. M.R. Picciotto Nicotine as a modulator of behavior: beyond the inverted U Trends Pharmacol Sci 24 2003 493 499
18. K.P. Mayhew, B.R. Flay, J.A. Mott Stages in the development of adolescent smoking Drug Alcohol Depend 59 Suppl 1 2000 S61 S81
19. C. Lerman, W. Berrettini Elucidating the role of genetic factors in smoking behavior and nicotine dependence Am J Med Genet 118B 2003 48 54
20. P.F. Sullivan, K.S. Kendler The genetic epidemiology of smoking Nicotine Tob Res 1 Suppl 2 1999 S51 S57, discussion S69-70
21. R.F. Tyndale Genetics of alcohol and tobacco use in humans Ann Med 35 2003 94 121
22. A.C. Heath, K.M. Kirk, J.M. Meyer, N.G. Martin Genetic and social determinants of initiation and age at onset of smoking in Australian twins Behav Genet 29 1999 395 407
23. J.R. Koopmans, W.S. Slutske, A.C. Heath, M.C. Neale, D.I. Boomsma The genetics of smoking initiation and quantity smoked in Dutch adolescent and young adult twins Behav Genet 29 1999 383 393
24. P.A. Madden, A.C. Heath, N.L. Pedersen, J. Kaprio, M.J. Koskenvuo, N.G. Martin The genetics of smoking persistence in men and women: a multicultural study Behav Genet 29 1999 423 431
25. C.N. Lessov, N.L. Benowitz, G.E. Swan Evidence for shared genetic risk between depressive symptoms and smoking experimentation in men [abstract] 2004 The Society In Proceedings of the Tenth Annual Meeting of the Society for Research on Nicotine and Tobacco; 2004 Feb 18-21; Scottsdale, Arizona. Scottsdale (AZ)
26. V. De Luca, A.H. Wong, D.J. Muller, G.W. Wong, R.F. Tyndale, J.L. Kennedy Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients Neuropsychopharmacology 29 2004 1522 1526
27. R. Freedman, L.E. Adler, P. Bickford, W. Byerley, H. Coon, C.M. Cullum Schizophrenia and nicotinic receptors Harv Rev Psychiatry 2 1994 179 192
28. L.E. Adler, L.J. Hoffer, J. Griffith, M.C. Waldo, R. Freedman Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics Biol Psychiatry 32 1992 607 616
29. R. Freedman, H. Coon, M. Myles-Worsley, A. Orr-Urtreger, A. Olincy, A. Davis Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus Proc Natl Acad Sci U S A 94 1997 587 592
30. G.R. Uhl, Q.R. Liu, D. Walther, J. Hess, D. Naiman Polysubstance abuse-vulnerability genes: genome scans for association, using 1,004 subjects and 1,494 single-nucleotide polymorphisms Am J Hum Genet 69 2001 1290 1300
31. M.D. Li, J.Z. Ma, R. Cheng, R.T. Dupont, N.J. Williams, K.M. Crews A genome-wide scan to identify loci for smoking rate in the Framingham Heart Study population BMC Genet 4 Suppl 1 2003 S103 S107
32. P.F. Sullivan, B.M. Neale, E. van den Oord, M.F. Miles, M.C. Neale, C.M. Bulik Candidate genes for nicotine dependence via linkage, epistasis, and bioinformatics Am J Med Genet 126B 2004 23 36
33. Wilhelmsen KC, Feiler HS, S-Cheng L, Lessov CN, Ring HZ, Jack LM, et al. A genome-wide search for quantitative trait loci associated with tobacco use phenotypes [abstract]. In Proceedings of the Tenth Annual Meeting of the Society for Research on Nicotine and Tobacco; 2004 Feb 18-21; Scottsdale, Arizona. Scottsdale (AZ): The Society; 2004.
34. D.E. Comings, K. Blum Reward deficiency syndrome: genetic aspects of behavioral disorders Prog Brain Res 126 2000 325 341
35. A.E. Goudriaan, J. Oosterlaan, E. de Beurs, W. Van den Brink Pathological gambling: a comprehensive review of biobehavioral findings Neurosci Biobehav Rev 28 2004 123 141
36. T. Arinami, H. Ishiguro, E.S. Onaivi Polymorphisms in genes involved in neurotransmission in relation to smoking Eur J Pharmacol 410 2000 215 226
37. V. Batra, A.A. Patkar, W.H. Berrettini, S.P. Weinstein, F.T. Leone The genetic determinants of smoking Chest 123 2003 1730 1739
38. C. Lerman, R. Niaura Applying genetic approaches to the treatment of nicotine dependence Oncogene 21 2002 7412 7420
39. N.L. Benowitz, S. Zevin, P. Jacob III Suppression of nicotine intake during ad libitum cigarette smoking by high-dose transdermal nicotine J Pharmacol Exp Ther 287 1998 958 962
40. J.E. Rose, W.A. Corrigall Nicotine self-administration in animals and humans: similarities and differences Psychopharmacology (Berl) 130 1997 28 40
41. R. Klink, A. de Kerchove d'Exaerde, M. Zoli, J.P. Changeux Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei J Neurosci 21 2001 1452 1463
42. H.N. Nguyen, B.A. Rasmussen, D.C. Perry Subtype-selective up-regulation by chronic nicotine of high-affinity nicotinic receptors in rat brain demonstrated by receptor autoradiography J Pharmacol Exp Ther 307 2003 1090 1097
43. M.R. Picciotto, M. Zoli, R. Rimondini, C. Lena, L.M. Marubio, E.M. Pich Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine Nature 391 1998 173 177
44. L.M. Marubio, A.M. Gardier, S. Durier, D. David, R. Klink, M.M. Arroyo-Jimenez Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors Eur J Neurosci 17 2003 1329 1337
45. B. Schilstrom, H.M. Svensson, T.H. Svensson, G.G. Nomikos Nicotine and food induced dopamine release in the nucleus accumbens of the rat: putative role of alpha7 nicotinic receptors in the ventral tegmental area Neuroscience 85 1998 1005 1009
46. G.G. Nomikos, B.E. Hildebrand, G. Panagis, T.H. Svensson Nicotine withdrawal in the rat: role of alpha7 nicotinic receptors in the ventral tegmental area Neuroreport 10 1999 697 702
47. Y. Feng, T. Niu, H. Xing, X. Xu, C. Chen, S. Peng A common haplotype of the nicotine acetylcholine receptor alpha 4 subunit gene is associated with vulnerability to nicotine addiction in men Am J Hum Genet 75 2004 112 121
48. K.K. Lueders, S. Hu, L. McHugh, M.V. Myakishev, L.A. Sirota, D.H. Hamer Genetic and functional analysis of single nucleotide polymorphisms in the beta2-neuronal nicotinic acetylcholine receptor gene (CHRNB2) Nicotine Tob Res 4 2002 115 125
49. M.J. McMorrow, R.M. Foxx Nicotine's role in smoking: an analysis of nicotine regulation Psychol Bull 93 1983 302 327
50. N.L. Benowitz, P. Jacob III Nicotine renal excretion rate influences nicotine intake during cigarette smoking J Pharmacol Exp Ther 234 1985 153 155
51. M.E. Jarvik, D.C. Madsen, R.E. Olmstead, P.N. Iwamoto-Schaap, J.L. Elins, N.L. Benowitz Nicotine blood levels and subjective craving for cigarettes Pharmacol Biochem Behav 66 2000 553 558
52. N.L. Benowitz, P. Jacob III Metabolism of nicotine to cotinine studied by a dual stable isotope method Clin Pharmacol Ther 56 1994 483 493
53. E.S. Messina, R.F. Tyndale, E.M. Sellers A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes J Pharmacol Exp Ther 282 1997 1608 1614
54. M. Nakajima, T. Yamamoto, K. Nunoya, T. Yokoi, K. Nagashima, K. Inoue Role of human cytochrome P4502A6 in C-oxidation of nicotine Drug Metab Dispos 24 1996 1212 1217
55. D. Dempsey, P. Tutka, P. Jacob III, F. Allen, K. Schoedel, R.F. Tyndale Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity Clin Pharmacol Ther 76 2004 64 72
56. M. Nakajima, T. Yamamoto, K. Nunoya, T. Yokoi, K. Nagashima, K. Inoue Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes J Pharmacol Exp Ther 277 1996 1010 1015
57. O. Pelkonen, A. Rautio, H. Raunio, M. Pasanen CYP2A6: a human coumarin 7-hydroxylase Toxicology 144 2000 139 147
58. C. Xu, S. Goodz, E.M. Sellers, R.F. Tyndale CYP2A6 genetic variation and potential consequences Adv Drug Deliv Rev 54 2002 1245 1256
59. H. Hadidi, Y. Irshaid, C.B. Vagbo, A. Brunsvik, S. Cholerton, K. Zahlsen Variability of coumarin 7- and 3-hydroxylation in a Jordanian population is suggestive of a functional polymorphism in cytochrome P450 CYP2A6 Eur J Clin Pharmacol 54 1998 437 441
60. M. Iscan, H. Rostami, M. Iscan, T. Guray, O. Pelkonen, A. Rautio Interindividual variability of coumarin 7-hydroxylation in a Turkish population Eur J Clin Pharmacol 47 1994 315 318
61. A. Rautio, H. Kraul, A. Kojo, E. Salmela, O. Pelkonen Interindividual variability of coumarin 7-hydroxylation in healthy volunteers Pharmacogenetics 2 1992 227 233
62. N.L. Benowitz, P. Jacob III Trans-3'-hydroxycotinine: disposition kinetics, effects and plasma levels during cigarette smoking Br J Clin Pharmacol 51 2001 53 59
63. T. Shimada, H. Yamazaki, F.P. Guengerich Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations Xenobiotica 26 1996 395 403
64. J.T. Kwon, M. Nakajima, S. Chai, Y.K. Yom, H.K. Kim, H. Yamazaki Nicotine metabolism and CYP2A6 allele frequencies in Koreans Pharmacogenetics 11 2001 317 323
65. M. Nakajima, J.T. Kwon, N. Tanaka, T. Zenta, Y. Yamamoto, H. Yamamoto Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans Clin Pharmacol Ther 69 2001 72 78
66. M. Nakajima, S. Yamagishi, H. Yamamoto, T. Yamamoto, Y. Kuroiwa, T. Yokoi Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans Clin Pharmacol Ther 67 2000 57 69
67. CYP2A6 allele nomenclaturefrom: URL http://www.imm.ki.se/CYPalleles/ cyp2a6.htm Accessed July 20, 2004
68. K. Schoedel, E. Hoffmann, Y. Rao, E. Sellers, R.F. Tyndale Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians Pharmacogenetics 14 2004 615 626
69. F.N. Hsia, D. Spruijt-Metz The meanings of smoking among Chinese American and Taiwanese American college students Nicotine Tob Res 5 2003 837 850
70. D. Spruijt-Metz, P.E. Gallaher, J.B. Unger, C. Anderson-Johnson Meanings of smoking and adolescent smoking across ethnicities J Adolesc Health 35 2004 197 205
71. M. Fujieda, H. Yamazaki, T. Saito, K. Kiyotani, M.A. Gyamfi, M. Sakurai Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers Carcinogenesis 25 2004 2451 2458
72. J.P. Zacny, M.L. Stitzer Cigarette brand-switching: effects on smoke exposure and smoking behavior J Pharmacol Exp Ther 246 1988 619 627
73. N.L. Benowitz, R.F. Tyndale, P. Jacob III, G.E. Swan CYP2A6 polymorphisms and nicotine metabolism [abstract] Clin Pharmacol Ther 71 2002 P41
74. Y. Rao, E. Hoffmann, M. Zia, L. Bodin, M. Zeman, E.M. Sellers Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking Mol Pharmacol 58 2000 747 755
75. M.L. Pianezza, E.M. Sellers, R.F. Tyndale Nicotine metabolism defect reduces smoking Nature 393 1998 750
76. R.F. Tyndale, E.M. Sellers Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk Drug Metab Dispos 29 2001 548 552
77. O.F. Pomerleau Individual differences in sensitivity to nicotine: implications for genetic research on nicotine dependence Behav Genet 25 1995 161 177
78. O.F. Pomerleau, A.C. Collins, S. Shiffman, C.S. Pomerleau Why some people smoke and others do not: new perspectives J Consult Clin Psychol 61 1993 723 731
79. O.F. Pomerleau, C.S. Pomerleau, R.J. Namenek Early experiences with tobacco among women smokers, ex-smokers, and never-smokers Addiction 93 1998 595 599
80. J.R. DiFranza, J.A. Savageau, K. Fletcher, J.K. Ockene, N.A. Rigotti, A.D. McNeill Recollections and repercussions of the first inhaled cigarette Addict Behav 29 2004 261 272
81. M. Ando, N. Hamajima, N. Ariyoshi, T. Kamataki, K. Matsuo, Y. Ohno Association of CYP2A6 gene deletion with cigarette smoking status in Japanese adults J Epidemiol 13 2003 176 181
82. N. Ariyoshi, M. Miyamoto, Y. Umetsu, H. Kunitoh, H. Dosaka-Akita, Y. Sawamura Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers Cancer Epidemiol Biomarkers Prev 11 2002 890 894
83. K. Iwahashi, C. Waga, T. Takimoto Whole deletion of CYP2A6 gene (CYP2A6*4C) and smoking behavior Neuropsychobiology 49 2004 101 104
84. N. Minematsu, H. Nakamura, M. Iwata, H. Tateno, T. Nakajima, S. Takahashi Association of CYP2A6 deletion polymorphism with smoking habit and development of pulmonary emphysema Thorax 58 2003 623 628
85. S.J. London, J.R. Idle, A.K. Daly, G.A. Coetzee Genetic variation of CYP2A6, smoking, and risk of cancer Lancet 353 1999 898 899
86. M.A. Loriot, S. Rebuissou, M. Oscarson, S. Cenee, M. Miyamoto, N. Ariyoshi Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population Pharmacogenetics 11 2001 39 44
87. S.Z. Sabol, D.H. Hamer An improved assay shows no association between the CYP2A6 gene and cigarette smoking behavior Behav Genet 157 1999 632 634
88. B. Carter, T. Long, P. Cinciripini A meta-analytic review of the CYP2A6 genotype and smoking behavior Nicotine Tob Res 6 2004 221 227
89. S. Goodz, J. Alhuwalia, K. Harris, C. Xu, Y.S. Rao, B. Xu CYP2A6 genetic variants among African-Americans. In Proceedings of the Eighth Annual Meeting of the Society for Research on Nicotine and Tobacco; 2002 Feb 20-23; Savannah, Georgia 2002 The Society Savannah (GA)
90. D.F. Gu, L.J. Hinks, N.E. Morton, I.N. Day The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit Ann Hum Genet 64 2000 383 390
91. J. O'Laughlin, G. Paradis, W. Kim, J.R. DiFranza, G. Meshefedijan, E. McMillan Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study in novice smokers Tob Control 13 2004 422 428
92. N.L. Benowitz, O.F. Pomerleau, C.S. Pomerleau, P. Jacob III Nicotine metabolite ratio as a predictor of cigarette consumption Nicotine Tob Res 5 2003 621 624
93. Y. Abreu-Villaca, F.J. Seidler, D. Qiao, C.A. Tate, M.M. Cousins, I. Thillai Short-term adolescent nicotine exposure has immediate and persistent effects on cholinergic systems: critical periods, patterns of exposure, dose thresholds Neuropsychopharmacology 28 2003 1935 1949
94. W. Adriani, S. Spijker, V. Deroche-Gamonet, G. Laviola, M. Le Moal, A.B. Smit Evidence for enhanced neurobehavioral vulnerability to nicotine during periadolescence in rats J Neurosci 23 2003 4712 4716
95. J.D. Belluzzi, A.G. Lee, H.S. Oliff, F.M. Leslie Age-dependent effects of nicotine on locomotor activity and conditioned place preference in rats Psychopharmacology (Berl) 174 2004 389 395
96. J.R. DiFranza, N.A. Rigotti, A.D. McNeill, J.K. Ockene, J.A. Savageau, D. St Cyr Initial symptoms of nicotine dependence in adolescents Tob Control 9 2000 313 319
97. B.J. Vastola, L.A. Douglas, E.I. Varlinskaya, L.P. Spear Nicotine-induced conditioned place preference in adolescent and adult rats Physiol Behav 77 2002 107 114
98. N. Breslau, E.O. Johnson Predicting smoking cessation and major depression in nicotine-dependent smokers Am J Public Health 90 2000 1122 1127
99. N. Hymowitz, K.M. Cummings, A. Hyland, W.R. Lynn, T.F. Pechacek, T.D. Hartwell Predictors of smoking cessation in a cohort of adult smokers followed for five years Tob Control 6 Suppl 2 1997 S57 S62
100. M. Ezzati, A.D. Lopez Estimates of global mortality attributable to smoking in 2000 Lancet 362 2003 847 852
101. P.E. McBride The health consequences of smoking Cardiovascular diseases Med Clin North Am 76 1992 333 353
102. R. Peto, S. Darby, H. Deo, P. Silcocks, E. Whitley, R. Doll Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies BMJ 321 2000 323 329
103. E.M. Sellers, R.F. Tyndale, L.C. Fernandes Decreasing smoking behaviour and risk through CYP2A6 inhibition Drug Discov Today 8 2003 487 493
104. Silagy C, Mant D, Fowler G, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2000;CD000146.
105. M.C. Fiore, S.S. Smith, D.E. Jorenby, T.B. Baker The effectiveness of the nicotine patch for smoking cessation A meta-analysis JAMA 271 1994 1940 1947
106. C.J. Patten, L.A. Peterson, S.E. Murphy Evidence for metabolic activation of N'-nitrosonornicotine and N-nitrosobenzylmethylamine by a rat nasal coumarin hydroxylase Drug Metab Dispos 26 1998 177 180
107. C.J. Patten, T.J. Smith, M.J. Friesen, R.E. Tynes, C.S. Yang, S.E. Murphy Evidence for cytochrome P450 2A6 and 3A4 as major catalysts for N'-nitrosonornicotine alpha-hydroxylation by human liver microsomes Carcinogenesis 18 1997 1623 1630
108. G.B. Smith, J.R. Bend, L.L. Bedard, K.R. Reid, D. Petsikas, T.E. Massey Biotransformation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in peripheral human lung microsomes Drug Metab Dispos 31 2003 1134 1141
109. H. Yamazaki, Y. Inui, C.H. Yun, F.P. Guengerich, T. Shimada Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes Carcinogenesis 13 1992 1789 1794
110. M.R. Law, J.K. Morris, H.C. Watt, N.J. Wald The dose-response relationship between cigarette consumption, biochemical markers and risk of lung cancer Br J Cancer 75 1997 1690 1693
111. T. Kamataki, K. Nunoya, Y. Sakai, H. Kushida, K. Fujita Genetic polymorphism of CYP2A6 in relation to cancer Mutat Res 428 1999 125 130
112. M. Miyamoto, Y. Umetsu, H. Dosaka-Akita, Y. Sawamura, J. Yokota, H. Kunitoh CYP2A6 gene deletion reduces susceptibility to lung cancer Biochem Biophys Res Commun 261 1999 658 660
113. H. Wang, W. Tan, B. Hao, X. Miao, G. Zhou, F. He Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK Cancer Res 63 2003 8057 8061
114. W. Tan, G.F. Chen, D.Y. Xing, C.Y. Song, F.F. Kadlubar, D.X. Lin Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population Int J Cancer 95 2001 96 101
115. E.M. Sellers, Y. Ramamoorthy, M.V. Zeman, M.V. Djordjevic, R.F. Tyndale The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone (NNK) metabolism in vivo Nicotine Tob Res 5 2003 891 899
116. E.D. Kharasch, D.C. Hankins, J.K. Taraday Single-dose methoxsalen effects on human cytochrome P-450 2A6 activity Drug Metab Dispos 28 2000 28 33
117. L.L. Koenigs, R.M. Peter, S.J. Thompson, A.E. Rettie, W.F. Trager Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen Drug Metab Dispos 25 1997 1407 1415
118. E.M. Sellers, R.F. Tyndale Mimicking gene defects to treat drug dependence Ann N Y Acad Sci 909 2000 233 246
119. H. Takeuchi, K. Saoo, M. Yokohira, M. Ikeda, H. Maeta, M. Miyazaki Pretreatment with 8-methoxypsoralen, a potent human CYP2A6 inhibitor, strongly inhibits lung tumorigenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone in female A/J mice Cancer Res 63 2003 7581 7583
120. E.M. Sellers, H.L. Kaplan, R.F. Tyndale Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking Clin Pharmacol Ther 68 2000 35 43
121. N. Ariyoshi, Y. Sawamura, T. Kamataki A novel single nucleotide polymorphism altering stability and activity of CYP2a6 Biochem Biophys Res Commun 281 2001 810 814
122. C. Xu, Y.S. Rao, B. Xu, E. Hoffmann, J. Jones, E.M. Sellers An in vivo pilot study characterizing the new CYP2A6*7,*8, and*10 alleles Biochem Biophys Res Commun 290 2002 318 324
123. Mwenifumbo JC, Myers MG, Wall T, Lin SK, Sellers EM, Tyndale RF. Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method. Pharmacogenetics. In press 2005.
124. H. Hadidi, K. Zahlsen, J.R. Idle, S. Cholerton A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin Food Chem Toxicol 35 1997 903 907
125. M. Oscarson, H. Gullsten, A. Rautio, M.L. Bernal, B. Sinues, M.L. Dahl Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase FEBS Lett 438 1998 201 205
126. N. Ariyoshi, Y. Takahashi, M. Miyamoto, Y. Umetsu, S. Daigo, T. Tateishi Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C Pharmacogenetics 10 2000 687 693
127. K.I. Nunoya, T. Yokoi, K. Kimura, T. Kainuma, K. Satoh, M. Kinoshita A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans J Pharmacol Exp Ther 289 1999 437 442
128. M. Oscarson, R.A. McLellan, H. Gullsten, Q.Y. Yue, M.A. Lang, M.L. Bernal Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population FEBS Lett 448 1999 105 110
129. K. Nunoya, T. Yokoi, K. Kimura, K. Inoue, T. Kodama, M. Funayama A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5- dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502) Pharmacogenetics 8 1998 239 249
130. M. Oscarson, R.A. McLellan, H. Gullsten, J.A. Agundez, J. Benitez, A. Rautio Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism FEBS Lett 460 1999 321 327
131. K. Kitagawa, N. Kunugita, M. Kitagawa, T. Kawamoto CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity J Biol Chem 276 2001 17830 17835
132. R. Yoshida, M. Nakajima, Y. Watanabe, J.T. Kwon, T. Yokoi Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism Br J Clin Pharmacol 54 2002 511 517
133. S. Daigo, Y. Takahashi, M. Fujieda, N. Ariyoshi, H. Yamazaki, W. Koizumi A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur Pharmacogenetics 12 2002 299 306
134. M. Oscarson, R.A. McLellan, V. Asp, M. Ledesma, M.L. Ruiz, B. Sinues Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity Hum Mutat 20 2002 275 283
135. K. Kiyotani, H. Yamazaki, M. Fujieda, S. Iwano, K. Matsumura, S. Satarug Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9) Pharmacogenetics 13 2003 689 695
136. M. Pitarque, O. von Richter, B. Oke, H. Berkkan, M. Oscarson, M. Ingelman-Sundberg Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity Biochem Biophys Res Commun 284 2001 455 460
137. R. Yoshida, M. Nakajima, K. Nishimura, S. Tokudome, J.T. Kwon, T. Yokoi Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro Clin Pharmacol Ther 74 2003 69 76
138. T. Paschke, M. Riefler, A. Schuler-Metz, L. Wolz, G. Scherer, C.M. McBride Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method Toxicology 168 2001 259 268
139. G.F. Chen, Y.M. Tang, B. Green, D.X. Lin, F.P. Guengerich, A.K. Daly Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction method Pharmacogenetics 9 1999 327 332